Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Spencer, Alexandra J ^a   Cottingham, Matthew G ^a   Jenks, Jennifer A ^a   Longley, Rhea J ^a   Capone, Stefania ^b   Colloca, Stefano ^b   Folgori, Antonella ^b   Cortese, Riccardo ^b,c   Nicosia, Alfredo ^b,d,e   Bregu, Migena ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Okairos ^*  (Italy)

^c Okairos AG C/o OBC Suisse AG ^*  (Switzerland)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD74 ANTIGEN; EPITOPE; HYBRID PROTEIN; MALARIA VACCINE; MALARIAL ANTIGEN; ME TRAP; PARASITE ANTIGEN; PROTEIN; THROMBOSPODIN RELATED ADHESION PROTEIN; UNCLASSIFIED DRUG; VACCINE; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; DRUG DEVELOPMENT; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; ANIMAL; C57BL MOUSE; CHICKEN; GENE VECTOR; HUMAN; IMMUNIZATION; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MALARIA, FALCIPARUM; MALE; METABOLISM; RHESUS MONKEY;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; CHICKENS; FEMALE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNIZATION; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MICE, INBRED C57BL; MICE, INBRED ICR; RECOMBINANT FUSION PROTEINS;

EID: 84903292693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100538     Document Type: Article

References (49)

1. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735. (Pubitemid 36749222)
2. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, et al. (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74: 5933-5942. (Pubitemid 44484581)
3. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, et al. (2005) Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102: 4836-4841. (Pubitemid 40471540)
4. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.
5. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, et al. (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra112.
6. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, et al. (2012) Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis 205: 772-781.
7. Hill AV (2006) Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 6: 21-32.
8. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, et al. (2005) Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 175: 5675-5680. (Pubitemid 41508049)
9. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, et al. (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836.
10. Germain RN (2011) Uncovering the role of invariant chain in controlling MHC class II antigen capture. J Immunol 187: 1073-1075.
11. Landsverk OJ, Bakke O, Gregers TF (2009) MHC II and the endocytic pathway: regulation by invariant chain. Scand J Immunol 70: 184-193.
12. Sponaas A, Carstens C, Koch N (1999) C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 6: 1826-1834. (Pubitemid 29531278)
13. Malcherek G, Wirblich C, Willcox N, Rammensee HG, Trowsdale J, et al. (1998) MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur J Immunol 28: 1524-1533. (Pubitemid 28221155)
14. Diebold SS, Cotten M, Koch N, Zenke M (2001) MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 8: 487-493. (Pubitemid 32266404)
15. Sanderson S, Frauwirth K, Shastri N (1995) Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci U S A 92: 7217-7221.
16. Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, et al. (2006) Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 13: 310-319. (Pubitemid 43056896)
17. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP (2011) Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 186: 2355-2364.
18. Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR (2009) Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 39: 2725-2736.
19. Grujic M, Holst PJ, Christensen JP, Thomsen AR (2009) Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. J Gen Virol 90: 414-422.
20. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, et al. (2008) MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 180: 3339-3346.
21. Jensen S, Steffensen MA, Jensen BA, Schluter D, Christensen JP, et al. (2013) Adenovirus-Based Vaccine against Listeria monocytogenes: Extending the Concept of Invariant Chain Linkage. J Immunol 191: 4152-4164.
22. Holst PJ, Christensen JP, Thomsen AR (2011) Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice. J Immunol 186: 3997-4007.
23. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet.
24. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeboost immunisation regimes. Vaccine 20: 1039-1045. (Pubitemid 34135938)
25. Rogers WO, Rogers MD, Hedstrom RC, Hoffman SL (1992) Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Mol Biochem Parasitol 53: 45-51.
26. Cottingham MG (2012) Genetic manipulation of poxviruses using bacterial artificial chromosome recombineering. Methods Mol Biol 890: 37-57.
27. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, et al. (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7: e40385.
28. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, et al. (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38: 732-741.
29. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, et al. (2006) Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80: 5875-5885. (Pubitemid 43849165)
30. Vojnov L, Martins MA, Almeida JR, Ende Z, Rakasz EG, et al. (2011) GagCM9-specific CD8+ T cells expressing limited public TCR clonotypes do not suppress SIV replication in vivo. PLoS One 6: e23515.
31. Roederer M, Nozzi JL, Nason MC (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
32. Burbelo PD, Ching KH, Klimavicz CM, Iadarola MJ (2009) Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS). J Vis Exp.
33. Brandler P, Saikh KU, Heath D, Friedlander A, Ulrich RG (1998) Weak anamnestic responses of inbred mice to Yersinia F1 genetic vaccine are overcome by boosting with F1 polypeptide while outbred mice remain nonresponsive. J Immunol 161: 4195-4200. (Pubitemid 28469001)
34. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850. (Pubitemid 47038186)
35. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258. (Pubitemid 351432801)
36. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, et al. (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 105: 14017-14022.
37. Spencer AJ, Hill F, Honeycutt JD, Cottingham MG, Bregu M, et al. (2012) Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One 7: e33555.
38. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, et al. (2008) Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82: 4844-4852. (Pubitemid 351657046)
39. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
40. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, et al. (2002) Development and homeostasis of T cell memory in rhesus macaque. J Immunol 168: 29-43. (Pubitemid 34014099)
41. WHO (2011) World Malaria Report 2011.
42. Hill AV (2011) Vaccines against malaria. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences 366: 2806-2814.
43. Moorthy VS, Ballou WR (2009) Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 8: 312.
44. Cresswell P (1996) Invariant chain structure and MHC class II function. Cell 84: 505-507.
45. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, et al. (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
46. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, et al. (2010) Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
47. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J (2013) High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis.
48. Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, et al. (2013) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis.
49. Capone S, Naddeo M, D'Alise AM, Abbate A, Grazioli F, et al. (2014) Fusion of HCV Nonstructural Antigen to MHC Class II-associated Invariant Chain Enhances T-cell Responses Induced by Vectored Vaccines in Nonhuman Primates. Mol Ther.